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Summary Objective: To determine and compare antimicrobial susceptibility pat-
terns of pathogenic bacteria from inpatients and outpatients at a university teaching
hospital in Yaounde, Cameroon.
Methods: Gram-negative bacilli isolates (n = 522), obtained from a wide range of
clinical specimens (urine, pus and blood) from inpatients and outpatients at Yaounde
Central Hospital between March 1995 and April 1998, were evaluated for resistance
to antibiotics (amoxicillin, amoxicillin/clavulanate, piperacillin, cefazolin, cefoxitin,
cefotaxime, ceftazidime, aztreonam, imipenem, gentamicin, tobramicin, oﬂoxacin
and trimethoprim/sulfamethoxazole).
Results: Of the 522 isolates recorded, 80.3% were Enterobacteriaceae. A high in-
cidence of resistance to amoxicillin (85%), piperacillin (75%) and trimethoprim/sul-
famethoxazole (71%) was observed. The proportion of antimicrobial-resistant isolates
from inpatients was signiﬁcantly higher than that from outpatients (P < 0.05), except
for piperacillin, tobramicin and trimethoprim/sulfamethoxazole. The combinations
of antimicrobial and organism showed that the percentage of ceftazidime-resistant
Pseudomonas aeruginosa and ceftazidime-resistant Enterobacter cloacae were 26.8%
and 24% respectively. The rate of antimicrobial resistance in isolates from inpa-
tients was not signiﬁcantly higher than that in isolates from outpatients for all the
antimicrobial/organism combinations, except for ceftazidime-resistant Escherichia
coli, which was exclusively found in isolates from inpatients. Among Enterobacte-
riaceae, high and low level penicillinase (mostly in E. coli (13.6% and 11% respec-
tively) and Klebsiella spp. (9% and 8% respectively) were the most important -lactam
resistance phenotypes (31.2% and 23.6%, respectively). Wild type (exclusively ob-
served in E. coli, Proteus mirabilis and Salmonella spp.) and low level penicillinase
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were higher in outpatient than inpatient isolates (wild type–—17.9% vs 10.8% and
low level penicillinase–—29.4% vs 20.5%, respectively; P < 0.05). However, extended
spectrum -lactamase strains (Klebsiella spp. (3.5%), E. coli (2.6%), Citrobacter spp.
(0.7%), Enterobacter spp. (0.4%) and P. mirabilis (0.2%)) were exclusively recovered
from inpatients. Penicillinase and high level cephalosporinase resistance phenotypes
were frequently observed in non-fermenter Gram-negative bacilli (46.6% and 29.1%
respectively). However, there were no signiﬁcant differences in penicillinase and
cephalosporinase resistance between inpatient and outpatient isolates.
Conclusion: As the incidence of antimicrobial resistance is substantially higher in
isolates from inpatient than outpatient pathogens, more resources should be allocated
within the hospital to encourage good antibiotic practices and good hospital hygiene.
© 2004 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
Introduction
Antimicrobial-resistant bacteria are the cause of
numerous clinical problems worldwide. The devel-
opment and the increase of antimicrobial resistance
among microbial pathogens causing nosocomial and
community-acquired infections is known to be asso-
ciated with the level of antibiotic use.1 Most stud-
ies have found a higher prevalence of antimicrobial
resistance in hospitals than in the community.2—4
The strategy for the control of antimicrobial resis-
tance lies mainly in the implementation of effective
infection control measures and antibiotic auditing.
For these measures, it is important to have data on
the identiﬁcation and resistance patterns of clini-
cal bacteria, and to know the magnitude of antimi-
crobial resistance in hospitals compared with that
in the community. These data may help to establish
preventive and therapeutic guidelines for clinicians
when appropriate.5,6
This studywas designated to evaluate and to com-
pare the resistance of Gram-negative bacilli caus-
ing nosocomial and community-acquired infections
in Yaounde Central Hospital, Cameroon.
Materials and methods
Study design and patients
To monitor the antimicrobial resistance patterns
of nosocomial and community-acquired infections,
relevant data from Yaounde Central Hospital (YCH)
concerning Gram-negative bacilli isolated from
inpatients and outpatients were analysed. The
study was carried out prospectively between March
1995 and April 1998. YCH is a university teaching
hospital with about 500 beds containing several
departments, including: medicine, surgery, inten-
sive care, obstetrics/gynaecology, paediatrics and
emergency. Patients included in this study were
registered on a study investigation form with de-
tails of name, age, sex, hospital department, date
of admission, diagnosis on admission, antibiotic
prophylaxis or treatment and clinical specimens.
This form was completed with the results of lab-
oratory diagnosis and data of antimicrobial sus-
ceptibility tests. After laboratory diagnosis, we
excluded patients without Gram-negative bacilli.
Bacterial isolates
A total of 522 Gram-negative bacilli isolates iso-
lated between 1995 and 1998 were obtained from
a wide range of clinical specimens including urine,
pus and blood from inpatients and outpatients.
Only one isolate per patient was studied. Organ-
isms were identiﬁed by conventional methods7 and
conﬁrmed by API 20E (bioMérieux France). Noso-
comial infections were diagnosed on the basis of
clinical and laboratory data. Isolates recovered
from patients at least 48 hours after admission
were considered nosocomial. Community-acquired
infections were diagnosed on admission and from
ambulatory care. The isolates studied included Es-
cherichia coli, Klebsiella pneumoniae, K. oxytoca,
Proteus mirabilis, indole positive Proteus spp.,
Providencia spp., Salmonella spp., Shigella spp.,
Pseudomonas spp., Acinetobacter baumannii and
Flavobacterium meningosepticum.
Susceptibility testing
Antimicrobial susceptibilities were determined by
Kirby—Bauer disk diffusion following the deﬁni-
tion of National Committee of Clinical Laboratory
Standards (NCCLS) for agar diffusion tests.8 The
antibiotics tested were amoxicillin, amoxicillin/
clavulanate, piperacillin, imipenem, cefazolin,
cefoxitin, cefotaxime, ceftazidime, gentamicin,
tobramycin, oﬂoxacin, and trimethoprim/sulfame-
thoxazole.
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E. coli American Type Culture Collection (ATCC)
25922 and P. aeruginosa ATCC 27853 were tested
along with the isolates for quality control purposes.
Test results were only accepted when inhibition
zone diameters of the control strains were within
performance ranges.8 The data were stratiﬁed by
all inpatients and all outpatients.
Antimicrobial/organism combinations and
β-lactam resistance phenotype
We studied the following antimicrobial/organism
combinations, taking into account their current
and potential clinical importance based on the re-
sults of antimicrobial susceptibility tests. These
combinations included: ceftazidime/E. coli; cef-
tazidime/Klebsiella spp.; ceftazidime/Enterobacter
cloacae; ceftazidime/Pseudomonas aeruginosa;
imipenem/P. aeruginosa.
The -lactam resistance phenotypes were deter-
mined using the results of antimicrobial suscepti-
bility tests.9,10 Resistance phenotypes were deﬁned
as follows:
For Enterobacteriaceae:
• Wild type: strain susceptible to all -lactams
used.
• Penicillinase phenotype: strains resistant to
amoxicillin and piperacillin and moderately re-
sistant to cefazolin.
• High level penicillinase: strains resistant to amox-
icillin, amoxicillin/clavulanate, piperacillin and
cefazolin.
• Inhibitor-resistant TEM phenotype: strains resis-
tant to amoxicillin, amoxicillin/clavulanate and
piperacillin.
• Low level cephalosporinase: strains resistant to
amoxicillin, amoxicillin/clavulanate, cefazolin,
and cefoxitin.
• High level cephalosporinase: strains resis-
tant to amoxicillin, amoxicillin/clavulanate,
piperacillin, cefazolin, cefoxitin, moderately
resistant to cefotaxime, ceftazidime and aztre-
onam.
• Extended spectrum -lactamase: strains resis-
tant to amoxicillin, amoxicillin/clavulanate,
piperacillin, cefazolin, cefotaxime, ceftazidime
and aztreonam. We conﬁrmed this phenotype by
the double disk synergy test.11
For non-fermenter Gram-negative bacilli:
• Penicillinase: strains resistant or moderately
resistant to piperacillin, cefotaxime and aztre-
onam.
• High level cephalosporinase: strains resistant
to piperacillin, cefotaxime, aztreonam and cef-
tazidime.
• Low level cephalosporinase: strains resistant to
cefotaxime.
As with the data of susceptibility tests, the data
of -lactam resistance phenotype were stratiﬁed by
all inpatients and all outpatients. The -lactam re-
sistance phenotype of organisms from hospitalised
patients was compared with that of isolates from
outpatients.
Statistics
Data were analysed using Whonet 4 (World Health
Organisation, Geneva, Switzerland) and Epi Info
version 6.04c (Centers for Disease Control and Pre-
vention, Atlanta, GA, USA). The Mantel-Haenszel
chi-squared test was used and the 2-tailed Fisher’s
exact test was used when an expected value was
less than 5. A P value of less than 0.05 was consid-
ered signiﬁcant.
Results
Enterobacteriaceae constituted 80.3% of the 522
isolates. The distribution of bacterial species by
clinical specimens and origin is presented in Table 1.
E. coli was the predominant pathogen isolated from
both inpatients and outpatients, representing 25.9%
and 43.4% of all isolates, respectively. The major-
ity of isolates (67.4%) were nosocomial. From in-
patients, pathogens were mostly isolated from pus
(50.9%) while the outpatient strains were mostly
from urine (56.5%).
The results of susceptibility to antibiotics of
different strains showed that the highest rates of
resistance (resistant plus intermediate) were to
amoxicillin (85%), piperacillin (73%) and trimetho-
prim/sulfamethoxazole (71%) (Table 2).
Except for piperacillin, tobramicin and trimetho-
prim/sulfamethoxazole, the occurrence of resis-
tance in isolates from inpatients was signiﬁcantly
higher than that in isolates from outpatients; for
trimethoprim/sulfamethoxazole, the occurrence of
resistance in isolates from outpatients was higher
than that in isolates from inpatients (Table 3).
In all, 419 isolates of Enterobacteriaceae were
collected (80.3%). The incidence of resistance to
amoxicillin, amoxicillin/clavulanate, piperacillin,
cefazolin and trimethoprim/sulfamethoxazole
were 85%, 62%, 73%, 69% and 71% respectively
(Table 2). More than 85% were susceptible to third
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Table 1 Distribution (%) of bacterial species by clinical specimen and origin.
Bacterial species
(n = 522) (%)
Inpatient
n = 352
(67.4)
Outpatient
n = 170
(32.6)
Clinical specimens
Urine Pus Blood
Inpatient
n = 145 (41.2)
Outpatient
n = 96 (56.5)
Inpatient
n = 179 (50.9)
Outpatient
n = 68 (40.0)
Inpatient
n = 28 (8.0)
Outpatient
n = 6 (3.5)
Escherichia coli 25.9 43.4 37.9 53.1 19.0 30.9 7.1 0.0
Klebsiella spp. 18.2 19.1 18.6 16.7 15.6 20.6 32.1 50.0
Proteus spp. 15.9 12.7 14.5 12.5 19.0 14.7 3.6 0.0
Enterobacter spp. 8.8 5.2 8.3 5.2 8.9 4.4 10.7 16.7
Citrobacter spp. 4.8 5.2 6.2 4.2 4.5 7.4 0.0 0.0
Pseudomonas spp. 17.9 8.7 9.0 3.1 25.7 14.7 14.3 33.3
Acinetobacter baumannii 5.7 2.3 2.8 2.1 6.1 2.9 17.9 0.0
Othersa 2.8 3.5 2.8 3.0 1.2 4.4 14.3 0.0
n: number of strains.
a Serratia spp., Salmonella spp., Shigella spp. and Flavobacterium meningosepticum.
Antimicrobial resistance of Gram-negative bacilli isolates 151
Table 2 Antimicrobial susceptibility (%) of 522 strains of Gram-negative bacilli.
Antibiotics Breakpoints Number of
isolates tested
Susceptibility (%)
Resistant Intermediate Susceptible
Amoxicillina 14—17 419 83 2 15
Amoxicillin/clavulanatea 14—17 419 30 32 38
Piperacillin 18—20 522 65 8 27
Cefazolina 15—17 419 53 16 31
Cefoxitina 15—17 419 20 6 74
Cefotaxime 15—22 522 15 18 67
Ceftazidime 15—17 522 9 5 86
Aztreonam 16—21 522 16 11 73
Imipenem 14—15 522 1 1 98
Gentamicin 13—14 522 30 3 67
Tobramycinb 13—14 96 42 2 56
Oﬂoxacin 13—15 522 9 2 89
Trimethoprim/sulfamethoxazolea 11—15 419 69 2 29
a Only tested against Enterobacteriaceae.
b Only tested against non-fermenter Gram-negative bacilli.
generation cephalosporins, oﬂoxacin and imipenem.
As for Gram-negative bacilli, the inpatients’ iso-
lates presented a signiﬁcantly higher rate of
antimicrobial resistance than the outpatients’
isolates, except for imipenem and trimetho-
prim/sulfamethoxazole (1.9% vs 0%, 70.9% vs 72.8%,
respectively). For non-fermenter Gram-negative
bacilli, a total of 103 isolates were collected
(19.7%). High rates of resistance were observed to
cefotaxime, aztreonam and piperacillin (95%, 77%
and 64%, respectively). A high proportion of iso-
lates were susceptible to imipenem (95%) whereas
Table 3 Antimicrobial resistance in Gram-negative bacilli isolates from inpatients vs outpatients.
Antibiotics Number of resistant isolates/total of
number of isolates tested (%)
P value
Inpatients Outpatients
Amoxicillin 239/268 (89.2) 120/151 (79.5) <0.01
Amoxicillin/clavulanate 182/268 (67.9) 79/151 (52.3) <0.01
Piperacillin 264/352 (75.0) 116/170 (68.2) 0.10a
Cefazolin 201/268 (75.0) 88/151 (58.2) <0.01
Cefoxitin 86/268 (32.1) 26/151 (17.2) <0.01
Cefotaxime 141/352 (40.0) 32/170 (18.8) <0.01
Ceftazidime 63/352 (17.9) 14/170 (8.2) <0.01
Aztreonam 120/352 (34.1) 21/170 (12.3) <0.01
Imipenem 11/352 (3.1) 0/170 (0.0) 0.01
Gentamicin 137/352 (38.9) 32/170 (18.8) <0.01
Tobramycin 36/77 (46.7) 5/19 (26.3) 0.10a
Oﬂoxacin 53/352 (15.0) 7/170 (4.1) <0.01
Trimethoprim/sulfamethoxazole 190/268 (70.9) 110/151 (72.8) 0.67a
a Not signiﬁcant.
only 70% were susceptible to oﬂoxacin and 63% to
ceftazidime. However, the proportion of antimi-
crobial resistance in isolates from inpatients was
not signiﬁcantly higher than that in isolates from
outpatients except cefotaxime (96.4% vs 10.5%,
respectively, p < 0.001).
Many phenotypes of resistance to -lactams
(wild type, low level penicillinase, high level
penicillinase, inhibitor-resistant TEM, low level
cephalosporinase, high level cephalosporinase
and extended spectrum -lactamase) were iden-
tiﬁed. For Enterobacteriaceae, high and low
152 J.G. Pie´boji et al.
Table 4 Resistance to speciﬁc antimicrobials in isolates from inpatients vs outpatients for antimicrobial/pathogen
combinations.
Antimicrobial/pathogen combination Number of resistant isolates/total of
number of isolates tested (%)
P value
Inpatients Outpatients
Ceftazidime/Escherichia coli 9/91 (9.9) 0/72 (0.0) <0.01
Ceftazidime/Klebsiella pneumoniae 9/64 (14.1) 2/30 (6.7) 0.92a
Ceftazidime/Enterobacter cloacae 5/22 (22.7) 1/3 (33.3) 0.58a
Ceftazidime/Pseudomonas aeruginosa 16/56 (28.6) 2/11 (18.2) 0.73a
Imipenem/Pseudomonas aeruginosa 4/56 (7.1) 0/11 (0.0) 0.82a
a Not signiﬁcant.
level penicillinase, mostly observed in E. coli
(13.6% and 11%), and Klebsiella spp. (9% and
8%) were the most important resistance pheno-
types (31.2% and 23.6% respectively). Wild-type
(only observed in E. coli (6%), P. mirabilis (6%)
and Salmonella spp. (1%)), and low level peni-
cillinase phenotypes were recovered in signif-
icantly higher numbers from outpatients’ than
from inpatients’ isolates (wild type–—17.9% vs
10.8% and low level penicillinase 29.1% vs 20.5%,
respectively p < 0.05). However, extended spec-
trum -lactamase-producing strains (Klebsiella
spp. (3.5%), E. coli (2.6%), Citrobacter spp. (0.7%),
Enterobacter spp (0.4%) and P. mirabilis (0.2%))
were exclusively recovered from inpatients (11.9%,
p < 0.001).
For non-fermenter Gram-negative bacilli, peni-
cillinase (Pseudomonas spp. (37.8%), Acinetobacter
baumannii (8.7%)) and high level cephalospori-
nase (Pseudomonas spp. (15.5%) and A. baumannii
(13.6%)) were the most frequent resistance phe-
notypes (46.6% and 29.1% respectively). Low level
cephalosporinase (observed in Pseudomonas spp. —
18.4% of isolates) was more frequently observed
in outpatients’ than inpatients’ isolates (26.3% vs
17.8%) as was high level cephalosporinase (31.6%
vs 28.6%) while penicillinase was more frequently
found in isolates from inpatients than outpatients
(48.8% vs 42.1%). However, the difference between
these isolates was not signiﬁcant.
For antimicrobial/organism combinations the
proportion of ceftazidime-resistant P. aerugi-
nosa and ceftazidime-resistant E. cloacae were
26.8% and 24% respectively. The proportion of
antimicrobial resistance in isolates from inpa-
tients was not signiﬁcantly higher than that in
isolates from outpatients for all of the antimi-
crobial/organism combinations except for cef-
tazidime/E. coli. The imipenem-resistant P. aerugi-
nosa and ceftazidime-resistant E. coli isolates were
observed exclusively in isolates from inpatients
(Table 4).
Discussion
The study provides insights into the problem of
resistance in bacterial Gram-negative enteric
pathogens in inpatients and outpatients in YCH,
Cameroon. To our knowledge this is the ﬁrst study
in Cameroon determining antimicrobial susceptibil-
ity patterns of nosocomial and community-acquired
Gram-negative bacilli. Results have demonstrated
that in general, Gram-negative bacilli have high
rates of resistance to the commonly used antibi-
otics. A high incidence of resistance was expressed
by all bacilli to the penicillins, ﬁrst generation
cephalosporins and trimethoprim/sulfamethoxa-
zole. Many multi-resistant strains were detected.
The rates of antimicrobial resistance reported in
this study were much higher than those published
in developed countries but are similar to those
reported in other developing countries.9,12—17
Many factors have contributed to such high rates
of resistance, including misuse of antibiotics by
health professionals, unskilled practitioners and
laypersons, misuse of antibiotics by the public
(antibiotics can be purchased without prescrip-
tion), poor drug quality, unhygienic conditions
accounting for the spread of resistant bacteria,
and inadequate surveillance (lack of information
from routine antimicrobial susceptibility testing
of bacterial isolates and surveillance testing of
bacterial isolates and surveillance of antibiotic re-
sistance, all of which are crucial for good clinical
practice and for rational policies against antibiotic
resistance).18
Our analysis suggests that the rate of resistance
in nosocomial pathogens to a variety of antimicro-
bials, such as amoxicillin, amoxicillin/clavulanate,
cefazolin, cefoxitin, cefotaxime and gentamicin,
commonly used to treat nosocomial infections,
is signiﬁcantly higher in the hospital setting than
the outpatient setting. The high rate of antimicro-
bial resistance in pathogens isolated in the hos-
pital could possibly be explained by the selective
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effect of treatment with multiple antimicrobials
for a single patient, which may result in the am-
pliﬁcation of antimicrobial resistance in some
organisms.2,19
This study has demonstrated that the hospital
is the focus of antimicrobial resistance. However,
there were exceptions. The increasing percentage
of trimethoprim/sulfamethozaxole-resistant Enter-
obacteriaceae; ceftazidime-resistant non-fermen-
ter Gram-negative bacilli; inhibitor-resistant TEM
phenotype-resistant Enterobacteriaceae; high level
cephalosporinase phenotype-resistant non-fermen-
ter Gram-negative bacilli, and ceftazidime-resistant
E. cloacae among isolates from outpatients sug-
gest that some form of selection effect on
these isolates exists for the outpatients of this
hospital.2
Some authors have observed in the hospital set-
tings a strong correlation between ceftazidime
usage and occurrence of ceftazidime-resistant P.
aeruginosa and E. cloacae isolates.20—24 In this
study, the incidence of ceftazidime-resistant P.
aeruginosa and E. clocae isolates was high. How-
ever, information about ceftazidime usage in YCH
was not available.
The combination of trimethoprim-sulfamethoxa-
zole is extensively used in Africa owing to its an-
timicrobial spectrum of activity and its low cost.
In addition, resistant bacteria have been isolated
from the stool ﬂora of infants who have never been
exposed to antibiotics, in contrast to the situation
in well developed countries.25 This reﬂects the role
of poor sanitation in the emergence and dissemina-
tion of resistant strains.
The results conﬁrm previously reported ﬁndings
about the occurrence of high rates of resistance
of Gram-negative bacilli to -lactam antibiotics
and trimethoprim/sulfamethoxazole in developing
countries, which are much higher than those ob-
served in developed countries. As the incidence of
antimicrobial resistance is higher in inpatients’ than
outpatients’ pathogens and because infection con-
trol measures may be difﬁcult to implement, more
resources should be allocated in the Cameroon to
stem possible problems within hospitals, includ-
ing good antibiotic practices and improvements in
hygiene.
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